quechua880's Journal

Bestbets: are young infants cured with erythromycin at risk for developing hypertrophic pyloric sten
Will be the [young infants] [exposed to erythromycin] [at risk for developing hypertrophic pyloric stenosis]Clinical Scenario
A 5-week-old infant is admitted to a high dependency unit with paroxysmal cough connected with dusky episodes. The severity and frequency of cough paroxysm increases and 48 h later pernasal swab confirms the diagnosis of pertusis. You want to treat the infant with erythromycin. However, you've heard that erythromycin can cause hypertrophic pyloric stenosis in young infants. allopurinol online without a prescription Which means you elect to learn more before commencing the treatment. Search Strategy
Medline (19512006) via Dialog DATA star:

Keywords: erythromycin or maciolides AND pyloric stenosis or infantile hypertrophic pyloric stenosis.
Limits: Human and English
Embase and Pubmed: Same search strategy used. No further relevant papers found.
Cochrane Database and Bestbets website: No further papers found. Search Outcome
A total of 30 articles put together. Every one of the abstracts were read and six relevant articles were identified for that analysis (table).
One systematic review as part of the analysis was primarily created to think about the use of erythromycin like a prokinetic agent in preterm infants (Patole). Another systemic review (Ng) checking out the by using erythromycin for the same was read however, not included in the analysis. This review included only two studies. A type of was contained in the other systemic review, analysed here, and the second study was published only in abstract form, plus the possible association between erythromycin and pyloric stenosis had not been discussed. Three other relevant case reports (Stang,Yuhko, Wimol) were read but not contained in the analysis as a consequence of small sample sizes in all ones. Relevant Paper(s)
Author, date and country
Patient group
Study type (amount of evidence)
Outcomes
Key results
Study Weaknesses
SanFillipo,
1976,
USA963 live births at Naval Hospital, Great Lakes, between November 1972 and October 1973. Every one of the infants with confirmed pyloric stenosis do your best were identifiedRetrospective cohort study (level IIb)Association between erythromycin use and development of pyloric stenosisFive of six infants with operative confirmed pyloric stenosis received erythromycin estolate at a dose of 40 mg/kg/day for superficial skin illness between 8 and 17 days of lifeSmall sample size
Retrospective study
No controls
Detailed discussion with all the different cases was reported
No specific information was handed on the prevalence of erythromycin use among infants who did not develop IHPSHonein et al,
1999,
USA282 infants born in Jan Feb 1999 for a community hospitalRetrospective cohort study and case review (level IIb)
157 of those were given erythromycin as post pertusis exposure prophylaxis whereas 125 were not given erythromycinAssociation between erythromycin use and progression of pyloric stenosisAbsolute risk of IHPS was 5. 1% for infants who took erythromycin for 814 days and 10% for infants who took it for 1521 days

Risk did not differ by erythromycin preparation (ethylsuccinate or estolate)

The seven index cases were a kid right at that moment erythromycin started (median Five days) as opposed to unaffected infants confronted with erythromycin (median 13 days, mean 14. 1 days)A blinded independent writeup on ultrasonography scans in the seven IHPS cases identified at surgery, and seven negative ultrasonography scans in the pylorus in the same hospital through the same period was obtained to validate the verification. All of the seven index cases with IHPS were weighed against historical IHPS cases at the two hospitals in the area when pyloromyotomies were performedMahon et al,
2001,
USA14 876 Infants born at an urban hospital from June 1993 through December 1999. Infants who died in first 3 months of life and infants who failed to receive care from the study network were excluded from your study. An overall of 469 infants were prescribed systemic erythromycin, 124 erythromycin ophthalmic ointment and 3346 mothers were prescribed systemic erythromycinRetrospective cohort (level IIb)Association between erythromycin use and progression of pyloric stenosisInfants who were prescribed systemic erythromycin had increased risk of IHPS with the highest risk in the first 2 weeks of life (relative risk = 10. 51, 95% CI 4. 48 to 24. 66)

Prescriptions of for a longer time of treatment (>14 days) were related to greater risk (p<0. 05). Erythromycin ophthalmic ointment use was not associated with increased risk of IHPS

There were inconclusive data relevant to the association between maternal use of macrolides within 10 weeks of delivery and IHPSRetrospective study
Decent sample size
No specific information was obtained to assess the compliance with all the treatmentCooper et al,
2002,
USAMedicaid or TennCare (Tennessee's program for Medicaid enrolees and uninsured individuals) births in Tennessee from 1985 to 1997 (314 029 infants)
The many infants using a proper diagnosis of pylorics stenosis at hospital discharge along with an associated medical operation were identified. Exposure to erythromycin or any other antibiotics between 3 and 3 months of life was identified from prescription files
Among 314 029 infants going to Medicaid, 804 (2. 6/100 infants) met the factors for pyloric stenosisRetrospective cohort study (level IIb)Association between erythromycin use and growth and development of pyloric stenosisVery early experience of erythromycin (between 3 and 13 events of life) was related to nearly eightfold increased probability of pyloric stenosis (adjusted incidence rate, 7. 88; 95% CI 1. 97 to 31. 57)

Exposure to erythromycin before Three months of life was from a twofold increase likelihood of pyloric stenosis (adjusted rate ratio, 2. 05; 95% CI 1. 06 to 3. 97). No increased chance pyloric stenosis was affecting infants subjected to antibiotics apart from erythromycin. Retrospective study
Decent sample size
Infants built into Honein et al's study were not includedSorensen et al,
2003,
DenmarkAll women who had live or still births after 28 weeks of gestation between 1991 and 2000 inside Danish county of North Jutland
Data on drug exposure and IHPS on them all was extracted from National Health Service, Danish Birth Registry and hospital discharge registry
An overall total of 1166 expecting mothers were prescribed macrolides from birth to 90 days postnatally. 41 778 females who are not prescribed erythromycin acted as controlPopulation-based cohort study (level IIb)Association between erythromycin use and continuing development of pyloric stenosisThe by using macrolides during nursing raises the probability of IHPS

The odds ratio for IHPS varied between 2. 3 and three in line with different periods of postnatal exposure, and after stratification for sex, we were holding 10. 3 (95% CI 1. 2 92. 3) for ladies and a pair of. 0 (95% CI 0. 5 8. 4) for boys. No specific information was obtained to assess compliance with treatment
Insufficient power
Discharge diagnosis inside the database found in the analysis usually are not entirely accurate, the proportion of misclassified cases in the used database is 515%. Patole et al,
2005,
AustraliaA total of seven studies checking out the by using erythromycin to be a prokinetic agent in preterm neonates involving 359 preterm neonates (<37 weeks). Systemic review (level Ia)Primary outcome: time taken to reach full enteral feeds. Secondary outcome: Erythromycin-related adverse side effects such as hypertrophic pyloric stenosisThe issue of erythromycin-related adverse effects cannot be considered adequately given the small sample size and insufficient data on long-term follow-up

None with the infants from available data developed hypertrophic pyloric stenosisIn three from the seven studies, erythromycin was adopted for a higher dose (>12 mg/kg/68 h). Inside the remaining four studies, it absolutely was used with a low dose (312 mg/kg/day). Comment(s)
Infantile hypertrophic pyloric stenosis is really a condition of early infancy during which hypertrophy of pylorus ends in gastric outlet obstruction. The aetiology in this condition remains unclear. Genetic predisposition acting jointly with environmental factors is easily the most widely accepted explanation. Erythromycin is a motilin receptor agonist. Many experts have hypothesised that erythromycin interacts with motilin receptors, inducing strong gastric and pyloric bulb contractions and leading to pylorus hypertrophy (Peeters, Jadcherla). Thus, it's plausible that young infants helped by erythromycin may be at increased risk for developing hypertrophic pyloric stenosis. Four cohort studies (table) were found that addressed this possible causal association. Them all were retrospective along methodological flaws, but unanimously suggested that young infants treated with a superior, antimicrobial dose of erythromycin (about 40 mg/kg/day) have reached risk for developing hypertrophic pyloric stenosis. The risk was reported to be substantially higher (810-fold) inside first A couple weeks of life in term or near-term infants and didn't differ by erythromycin preparations (ethylsuccinate or estolate). Infants cured with erythromycin for a longer time durations (>14 days) were found to become at and the higher than these treated for shorter durations. Erythromycin is excreted into breast milk, plus the level of erythromycin in breast milk is 50100% with the level in maternal plasma (Briggs). Thus it may not be unreasonable to suspect that maternal by using macrolides during nursing could also increase the risk of infantile hypertrophic pyloric stenosis. A large population-based cohort study (Sorenson) was discovered dealing with this question and suggested that this utilization of macrolides during breast feeding improves the risk of infantile hypertrophic pyloric stenosis. Newer macrolides, including azithromycin, recently gained popularity among clinicians with the shorter duration of treatment and much less gastrointestinal side effects than erythromycin. Only a small number of infants addressed with azithromycin following your first 6 weeks of life were in the study by Mahon et al. Undertake and don't developed pyloric stenosis. In another study,(Friedman) primarily meant to have a look at efficacy of azithromycin to be a post-pertusis exposure chemoprophylactic agent, 58 neonates received azithromycin. Do not require developed pyloric stenosis. Further evidence is essential before an obvious conclusion could be drawn regarding the use of newer macrolides and subsequent growth of pyloric stenosis. Erythromycin is used in preterm babies with feed intolerance in a few centres. A planned out review (Patole) studying the using erythromycin as being a prokinetic agent still did not evaluate the issue of erythromycin-related uncomfortable side effects, including pyloric stenosis adequately, considering the small sample size and insufficient data on long-term follow-up inside included studies. At this time, on the basis of published evidence, it can be concluded that young infants come across erythromycin in the first couple of weeks of life are in the upper chances for developing hypertrophic pyloric stenosis. The very best risk seems to be within the first 2 weeks of life in term or near-term infants, along with courses of >14 days. Infants confronted with erythromycin through breast milk may be vulnerable to developing hypertrophic pyloric stenosis, although further evidence is necessary to confirm this causal association. Erythromycin should basically be found in young infants (<4 weeks) when the therapeutic benefits outweigh the risks and no alternative agent is available
Editor Comment
IHPS, infantile hypertrophic pyloric stenosis. Authors note:I thank Dr Ros Jones, Consultant Paediatrician, Wexham Park Hospital, Slough, Berkshire, for her critical comments about the article. Clinical Bottom Line
Infants exposed to therapeutic doses of erythromycin in the first few weeks of life are at greater risk for developing hypertrophic pyloric stenosis (grade B). The highest risk seems to be in the first 2 weeks of life in term or near-term infants, and with courses of >14 days (grade B). Erythromycin given for feed intolerance is not clearly connected with HPS (grade D). References

SanFillippo JA. Infantile hypertrophic pyloric stenosis linked to ingestion of erythromycin estolate: a study of 5 cases. J Pediatr Surg 1976;11:1779.

Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertusis prophylaxis with erythromycin: an instance review and cohort study. Lancet 1999;354:21015.

Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant by using erythromycin and also other macrolide antibiotics as risks for infantile hypertrophic pyloric stenosis. J Pediatr 2001;139:3804.

Cooper WO, Griffin MR, Arbogast P, et al. Very early contact with erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:64750.

Sorensen HT, Skriver MV, Pedersen L, et al. Likelihood of infantile hypertrophic pyloric stenosis after maternal postnatal using macrolids. Scand J Infect Dis 2003;35:1046.

Patole S, Rao S, Doherty D. Erythromycin as being a prokinetic agent in preterm neonates: a systemic review. Arch Dis Child Fetal Neonatal Ed 2005;90:3016. 7.

Ng E, Shah V. Erythromycin for feeding intolerance in preterm infants. Cochrane Database Syst Rev 2001;(2):CD001815. buy amoxicillin online without prescription

Stang H. Pyloric stenosis regarding erythromycin ingested through breast milk. Minn Med 1986;69:66970.

Yuhko S, Hirokazu T, Ritsuyo K, et al. Erythromycin in ELBW infants. J Pediatr 2002;141:2978.

Wimol S, Nuntnarumit P, et al. Oral erythromycin for treatment of feeding intolerance in preterm infants: a primary report. J Med Assoc Thai 2002;85:117782.

Peeters T, Matthijs G, Depoortere I, et al. Eryhtromycin is usually a motilin receptor agonist. Am J Physiol 1989;257:4704.

Jadcherla S, Kleg G, Berseth C. Dangerous migrating motor complexes by motilin and pancreatic polupeptide in human infants. Pediatr Res 1997;42:3659.

Briggs GG, Freeman RK, Yaffe SJ. Drugs while pregnant and lactation: a reference self-help guide to fetal and neonatal risk. Baltimore, MD: Williams & Wilkins, 1998:394-5.

Friedman DS, Curtis RC, Schauer SL, et al. Surveillance for transmission and antibiotic adverse events among neonates and adults confronted with a healthcare worker with pertussis. Infect Control Hosp Epidemiol 2004;25:96773.

.

Current Mood: hungry